Data for this list of genetics stocks on the NASDAQ was collected on January 15, 2024, using TradingView’s stock screener, and stocks with market caps above US$50 million were considered. Allogene Therapeutics aims to develop allogeneic chimeric antigen receptor T-cell, or CAR-T, cancer therapy. However, the US Food and Drug Administration has placed the firm on hold. Exact is working on technologies to address the multi-cancer screening market, worth $25 billion, and the recurrence tracking industry, worth $15 billion. Exact said second-quarter sales of $435 million were up 62 percent yearly, compared to a deficit of $167 million.
NASDAQ: BEAM
- According to clinical data, at least one in six people have a variant spelling an underlying health condition.
- VERVE-102 targets PCSK9 and is designed to permanently turn off the PCSK9 gene in the liver.
- Gene-editing stocks are shares of biotechnology companies that focus on modifying DNA.
- Melissa holds a bachelor’s degree in English education as well as a master’s degree in the teaching of writing, both from Humboldt State University, California.
As the sequencing market expands from research to clinical applications, Illumina is developing tools to help physicians diagnose and select treatments for patients. Caribou Biosciences is a clinical-stage biotech firm developing allogeneic, or universal, gene-edited cell therapies for cancer. With technological advancements dramatically improving the cost, accuracy, and time to map a person’s entire genome, many rapidly growing companies are emerging in the genomics sector. This doesn’t always lead to financial rewards for investors, but there are several promising genomics stocks that could be long-term winners. The two companies are evaluating nexiguran ziclumeran (also known as NTLA-2001) in a phase 3 clinical study for the treatment of transthyretin amyloidosis (ATTR) with cardiomyopathy, a rare genetic disease. This experimental therapy has also advanced into another phase 3 study targeting hereditary ATTR amyloidosis with polyneuropathy.
- Believe it or not, an online broker is a financial institution designed to help customers purchase different securities such as stocks from one of the best trading platforms.
- Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days.
- One key competitive advantage it offers is that it markets the only sequencing technology that supports real-time analysis.
- Intellia will be eligible for milestone payments and royalties if the experimental therapy advances through clinical development and ultimately wins regulatory approval.
NASDAQ: EXAS
She helps to educate investors about opportunities in a variety of growth markets. Melissa holds a bachelor’s degree in English education as well as a master’s degree in the teaching of writing, both from Humboldt State University, California. Stoke’s first product candidate, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe genetic epilepsy. The company is also developing STK-002 for the treatment of autosomal dominant optic atrophy, an inherited optic nerve disorder.
About 255 participants will be included in the randomized, double-blind experiment, which will have a 52-week treatment duration and an open-label extension. SKYCLARYS is now the only approved therapy for FA in people aged 16 and up, and it is available in more than 40 countries. The BRAVE research seeks to address a large unmet need in pediatric FA. Ionis has taken a net loss (TTM) of $268 million for the period ending June 30, 2025. While it hasn’t been profitable so far, Ionis has several promising products in its drug pipeline and partnerships with large pharmaceutical companies.
Top 5 NASDAQ Genetics Stocks (Updated January
However, the long-term potential for Beam’s technology could justify this premium valuation. It initially took 13 years and $2.7 billion (in 1991 dollars) to map our DNA as part of the Human Genome Project. Since then, more sophisticated next-generation sequencing (NGS) technology enables an entire genome to be sequenced within a single day at a cost of less than $600.
Illumina, Inc. (NASDAQ:ILMN)
The company is evaluating three candidates in phase 1/2 clinical testing, targeting sickle cell disease, alpha-1 antitrypsin deficiency (AATD), and glycogen storage disease 1a (GSD1a), rare genetic disorders. Several gene-editing companies are also targeting various types of cancer. In particular, CRISPR is being used to develop chimeric antigen receptor (CAR) T-cell therapies, where immune cells are genetically engineered to attack specific tumors.
It specializes in antibody oligonucleotide conjugates (AOCs), which are able to deliver to previously inaccessible tissues and cell types and target genetic drivers of disease. In genomics stocks the second quarter of 2025, revenue increased by 32% year over year and the number of tests it processed increased by 12%. For the trailing 12 months (TTM) ending June 30, 2025, Natera earned $2 billion in revenue and $1.2 billion in gross profit. Of late, there have been several breakthroughs in this field, attracting the attention of pharma and biotech companies.
See More Zacks Research for These Tickers
In this article, we will discuss what genomics stocks are, their categories, and the best genomics stock options to consider for 2023. Lonvo-z (NTLA-2002) is an experimental in vivo CRISPR-based gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The FDA has designated it as an Orphan Drug and RMAT, while the EMA has designated it as PRIME, among other regulatory classifications. This Zacks Rank #2 (Buy) company is also advancing ex vivo applications to address immuno-oncology and autoimmune diseases, where CRISPR is used as the tool to create the engineered cell therapy outside the body. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The company’s market cap isn’t above the levels of other CRISPR stocks with more advanced pipelines.
The Human genome project, for example, has led to major breakthroughs in understanding diseases like cancer. And as our understanding of genetics continues to grow, the potential applications of genomics will only increase. For this article, we sifted through Genomics online rankings to form an initial list of the 20 Best Genomics Stocks. From the resultant dataset, we chose 11 stocks with the highest number of hedge fund investors, using Insider Monkey’s database of 1000 hedge funds in Q to gauge hedge fund sentiment for stocks. We have used the stock’s revenue growth year-over-year as a tie-breaker in case two or more stocks have the same number of hedge funds invested.
Shares in Avidity reached a yearly peak of US$52.50 on November 13, a day after the company introduced its first two precision cardiology development candidates targeting the root cause of genetic diseases of the heart. Because of technical progressions, sequencing costs have decreased by 28% each year. That said, for investors with a high tolerance for risk, genomics stocks could be worth a look. Below, we’ll take a closer look at some of the most promising categories of genomics companies. The company’s pipeline includes two allogeneic chimeric antigen receptor T cell (CAR-T) therapies in clinical testing — CTX112 and CTX131.
It has a strong cash position, primarily due to its partnership with Vertex, with an approved product on the market. Believe it or not, an online broker is a financial institution designed to help customers purchase different securities such as stocks from one of the best trading platforms. Jordan Blake is a cultural commentator and trending news writer with a flair for connecting viral moments to the bigger social picture. With a background in journalism and media studies, Jordan writes timely, thought-provoking content on everything from internet challenges and influencer scandals to viral activism and Gen Z trends.
The Regeneron Genetics Center is an AI-powered genetic research facility that uses one of the biggest genetic research databases in the world to help create novel treatments. A scientist in a lab conducting research on cell-based therapeutics and biotechnology. Discoveries made by companies in the genetics sector help support every other life science industry in a variety of ways. According to expert Jason Gerberry, a 75% chance of the suspension being lifted by mid-December is a significant bullish stock trigger. As a result, Bank of America has a “buy” rating and a $32 price objective for ALLO stock, which closed at $18.81 on November 22nd. In 2022, Vertex paid CRISPR $900 million based on the most recent trial findings, with the potential for an additional $200 million pending regulatory clearance.
And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors. While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock. The rapid growth expected in the genomic segments means there could be many winners. Investors can start by picking a company from the segment they find most attractive.
NTLA is leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. The in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Beam’s pipeline also features three other base-editing therapies in clinical development. Genetic sequencing companies are the engines underpinning the field of genomics and are a critical component of genetic research and genetic testing. Technology advancements are making sequencing cheaper, faster, and more accurate.